EMA Authorised: Junod (denosumab) — Gedeon Richter Plc.

View source ↗

Summary

Authorisation of Junod (denosumab) by Gedeon Richter Plc. for conditions related to bone resorption and osteoporosis, including postmenopausal osteoporosis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bone Resorption Disorders
• Osteoporosis
• Osteoporosis Postmenopausal

Drugs mentioned

• Junod (denosumab)

Snippet

Status: Authorised. Therapeutic area: Bone Resorption;Osteoporosis;Osteoporosis, Postmenopausal. MAH: Gedeon Richter Plc.. Decision date: 19/08/2026